<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901977</url>
  </required_header>
  <id_info>
    <org_study_id>2007-000631-25</org_study_id>
    <nct_id>NCT02901977</nct_id>
  </id_info>
  <brief_title>Doxazosin and Ramipril in Hypertension</brief_title>
  <acronym>DoRa</acronym>
  <official_title>On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized double-blind parallel group study in patients with mild-to-moderate hypertension
      to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks
      with ramipril or doxazosin on hemostatic mechanisms and on endothelial function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to answer the following questions: 1) Does antihypertensive therapy with
      doxazosin exhibit antithrombotic effects in patients with essential hypertension? 2) Are the
      potential antithrombotic effects of doxazosin different to the effects of an ACE inhibitor?
      3) Is there a relation between the antihypertensive effect and the antithrombotic effect of
      these antihypertensive agents?

      The co-primary outcomes are changes in endothelial function assessed by flow mediated
      vasodilatation, and in haemostatic function measured by the generation of
      thrombin-antithrombin complex.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin generation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Thrombin-Antithrombin complex (TAT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Forearm post-ischemic flow mediated dilatation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ACE inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril tablets 10 mg od for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha receptor blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxazosin tablets 8 mg od for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Antihypertensive therapy</description>
    <arm_group_label>ACE inhibitor</arm_group_label>
    <other_name>Tiratec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Antihypertensive therapy</description>
    <arm_group_label>Alpha receptor blocker</arm_group_label>
    <other_name>Alfadil ,Cardura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary mild-to-moderate hypertension

        Exclusion Criteria:

          -  Pregnancy and lactation

          -  Recent (6 months) malignant disease or ongoing treatment for malignancy

          -  No absolute indication or contraindication for any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kahan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>September 10, 2016</last_update_submitted>
  <last_update_submitted_qc>September 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Thomas Kahan</investigator_full_name>
    <investigator_title>Principal investigator, Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

